



(11) **EP 1 715 865 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Date of publication and mention
of the grant of the patent:
10.03.2010 Bulletin 2010/10

(21) Application number: **05710692.4**

(22) Date of filing: **18.02.2005**

(51) Int Cl.:
A61K 31/47 ^(2006.01) **A61K 31/202** ^(2006.01)
A61P 3/06 ^(2006.01)

(86) International application number:
PCT/JP2005/003092

(87) International publication number:
WO 2005/079797 (01.09.2005 Gazette 2005/35)

(54) **HYPERLIPEMIA THERAPEUTIC AGENT COMPRISING PITAVASTATINS AND
EICOSAPENTAENOIC ACID**

MITTEL ZUR BEHANDLUNG VON HYPERLIPIDÄMIE MIT PITAVASTATINEN UND
EICOSAPENTAENSÄURE

AGENT THERAPEUTIQUE CONTRE L'HYPERLIPÉMIE CONTENANT DES PITAVASTATINES ET
L'ACIDE EICOSAPENTAÉNOÏQUE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **19.02.2004 US 780640**

(43) Date of publication of application:
02.11.2006 Bulletin 2006/44

(73) Proprietors:
• **Kowa Company, Ltd.**
Nagoya-shi, Aichi-ken 460-8625 (JP)
• **Nissan Chemical Industries, Ltd.**
Chiyoda-ku,
Tokyo 101-0054 (JP)

(72) Inventors:
• **AOKI, Taro**
Tokorozawa-shi, Saitama 3590037 (JP)
• **YAMAGUCHI, Junji**
Higashimurayama-shi, Tokyo 1890022 (JP)
• **SASAKI, Yusuke**
Higashimurayama-shi, Tokyo 1890022 (JP)

(74) Representative: **Hartz, Nikolai et al**
Wächtershäuser & Hartz
Patentanwaltspartnerschaft
Weinstrasse 8
80333 München (DE)

(56) References cited:
• **"PITAVASTATIN ITAVASTATIN, NISVASTATIN,
NK 104, NKS 104, P 872441" DRUGS IN R & D,
ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 3,
no. 1, 2002, pages 58-60, XP008058974 ISSN:
1174-5886**
• **NORDOEY A ET AL: "N-3 POLYUNSATURATED
FATTY ACIDS AND CARDIOVASCULAR
DISEASES" LIPIDS, CHAMPAIGN, IL, US, vol. 36,
no. SUPPL, 2001, pages S127-S129, XP008060642
ISSN: 0024-4201**
• **DAS U N: "ESSENTIAL FATTY ACIDS AS
POSSIBLE MEDIATORS OF THE ACTIONS OF
STATINS" PROSTAGLANDINS LEUKOTRIENES
AND ESSENTIAL FATTY ACIDS, CHURCHILL
LIVINGSTONE MEDICAL JOURNALS,, GB, vol.
65, no. 1, July 2001 (2001-07), pages 37-40,
XP008060638 ISSN: 0952-3278**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 715 865 B8

- **NORDOY A ET AL:** "Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia" JOURNAL OF INTERNAL MEDICINE, vol. 243, no. 2, February 1998 (1998-02), pages 163-170, XP002371430 ISSN: 0954-6820
- **NORDOY A ET AL:** "EFFECTS OF ATORVASTATIN AND OMEGA-3 FATTY ACIDS ON LDL SUBFRACTIONS AND POSTPRANDIAL HYPERLIPEMIA IN PATIENTS WITH COMBINED HYPERLIPEMIA" NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, MILAN, IT, vol. 11, no. 1, February 2001 (2001-02), pages 7-16, XP008060643 ISSN: 0939-4753
- **YANO TAKASHI ET AL.:** "Effects of ethyl-all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits" LIFE SCIENCES, vol. 61, no. 20, 1997, pages 2007-2015,

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification